SecBot SecBot
8-K ·Filed Aug 10, 2026

QTRX

Quanterix Corp
BEARISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0001503274-26-000035
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The significant guidance cut and delayed cash-flow breakeven suggest the business is in a correction phase. Watch for further revenue shortfalls in H2 2026 and clinical utility study results/FDA decision on LucentAD Complete as potential catalysts. The new commercial leadership has not yet proven results.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.42
T+0 close · Aug 10, 2026 · via day close
Latest settled
+21.49%
T+60 · $2.94
Vs SPY
+23.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $2.42entry
  2. T+1 · 3mo ago +8.47%α +8.79% · $2.63
  3. T+5 · 3mo ago +20.66%α +20.71% · $2.92
  4. T+20 · 2mo ago +12.81%α +13.72% · $2.73
  5. T+60 · 14d ago +21.49%α +23.90% · $2.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Quanterix Q2 2026 revenue of $32.9M missed consensus estimates of $37.5M by 12.3%, driven by execution challenges and market softness. The company slashed full-year 2026 guidance to $142-148M from $169-174M, recorded a $26.9M goodwill impairment, and pushed cash-flow breakeven to 2027.

Key Financial Metrics

EPS
−$1.04
Revenue
$32.9M
est $37.5M · -12.3% · +34.4% YoY
Rating
strong miss
Guidance
$142M-$148M
lowered
Gross Margin
38.5%

Key Facts

  • Revenue of $32.9M missed the $37.5M consensus estimate by 12.3%
  • GAAP gross margin fell to 38.5% from 40.9% a year ago
  • Net loss widened to $48.9M vs $30.0M in Q2 2025, including a $26.9M goodwill impairment
  • EPS of ($1.04) per share on 47.2M shares, versus consensus of ($0.41) on a different share count, GAAP EPS not directly comparable to consensus
  • Full-year 2026 revenue guidance slashed to $142-148M from $169-174M
  • Cash-flow breakeven pushed to 2027 from H2 2026; year-end cash forecast lowered to ~$80M from ~$100M
  • Pro-forma revenue (including Akoya pre-acquisition) declined 23% year-over-year
  • Completed ERP integration and realized $85M in annualized cost synergies from Akoya acquisition
  • Appointed Jim Gute as Chief Commercial Officer; named other senior leaders

Financial Impact

Revenue guidance reduced by ~16% at midpoint ($145M vs $171.5M prior midpoint), implying $10M+ in lost revenue vs prior expectations. Cash balance expected to decline to ~$80M by year-end 2026 from $96.9M.

revenueepsguidancecashgoodwill

Risk Factors

  • Continued revenue shortfall from execution challenges and weak academic/pharma end markets
  • Cash burn could accelerate if revenue does not recover, potentially requiring dilutive financing
  • Failure to achieve 2027 cash-flow breakeven target
  • Goodwill impairment signals potential for further impairments on remaining goodwill

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001503274-26-000035
Exhibit: ex993-qtrxx20260630.htm0001503274-26-000035
Document: q2-26earningspresentatio.htm0001503274-26-000035
Document: qtrx-20260810.htm0001503274-26-000035
Document: 0001503274-26-000035-index-headers.html0001503274-26-000035
Document: 0001503274-26-000035-index.html0001503274-26-000035
Document: 0001503274-26-000035.txt0001503274-26-000035
8-K Data (Synthetic)0001503274-26-000035

Track record

7 reports on QTRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $3.28 Now $2.84 −13.41% settles Nov 17
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $3.38 to $2.84 Now $2.84 +15.98% ▲ +15.98% +14.28% vs SPY
  3. Aug 10, 202614w ago 8-K Bearish 8/10 Viewing Entry $2.42 to $2.92 Now $2.84 −17.36% ▼ −20.66% −20.71% vs SPY
  4. Jun 17, 202621w ago Institutional Cluster Bullish 5/10 Entry $2.88 to $3.78 Now $2.84 −1.39% ▲ +31.25% +32.29% vs SPY
  5. Jun 9, 202622w ago 8-K Neutral 3/10 Entry $3.09 to $3.10 Now $2.84 −8.09% ▲ +0.32% −2.09% vs SPY
  6. May 26, 202624w ago 8-K Neutral 2/10 Entry $2.65 to $3.53 Now $2.84 +7.17% ▲ +33.21% +32.74% vs SPY
  7. May 8, 202627w ago DEFA14A Neutral 2/10 Entry $2.80 to $2.52 Now $2.84 +1.43% ▼ −10.00% −9.91% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026